Back to News
Market Impact: 0.15
60 Degrees Pharma Expands Research Into Alpha-Gal Syndrome; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
60 Degrees Pharmaceuticals announced a sponsored research agreement with the University of Southern Mississippi to evaluate the therapeutic potential of castanos. The article excerpt provides no research results, financial terms, or expected timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
SXTP0.50
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off